KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Total Liabilities (2017 - 2025)

Novartis Ag (NVS) has disclosed Total Liabilities for 9 consecutive years, with $64.4 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 10.81% to $64.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.4 billion through Dec 2025, up 10.81% year-over-year, with the annual reading at $64.4 billion for FY2025, 10.81% up from the prior year.
  • Total Liabilities hit $64.4 billion in Q4 2025 for Novartis Ag, up from $58.1 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $64.4 billion in Q4 2025 to a low of $53.2 billion in Q4 2023.
  • Historically, Total Liabilities has averaged $59.5 billion across 5 years, with a median of $58.1 billion in 2024.
  • Biggest five-year swings in Total Liabilities: decreased 10.04% in 2021 and later rose 10.81% in 2025.
  • Year by year, Total Liabilities stood at $64.0 billion in 2021, then dropped by 9.29% to $58.0 billion in 2022, then decreased by 8.33% to $53.2 billion in 2023, then grew by 9.26% to $58.1 billion in 2024, then increased by 10.81% to $64.4 billion in 2025.
  • Business Quant data shows Total Liabilities for NVS at $64.4 billion in Q4 2025, $58.1 billion in Q4 2024, and $53.2 billion in Q4 2023.